Pure Global

Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease - Trial NCT06079190

Access comprehensive clinical trial information for NCT06079190 through Pure Global AI's free database. This Phase 2 trial is sponsored by GlaxoSmithKline and is currently Not yet recruiting. The study focuses on Alzheimer's Disease. Target enrollment is 282 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06079190
Phase 2
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06079190
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease
A Phase 2, Parallel Group, Randomized, Double- Blind, Placebo-Controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101] Intravenous Infusion Compared With Placebo in Patients With Early Alzheimer's Disease

Study Focus

Alzheimer's Disease

GSK4527226

Interventional

drug

Sponsor & Location

GlaxoSmithKline

San Diego,DeLand,Maitland,Miami,Orlando,Stuart,The Villages,Wellington,Decatur,Elk Grove Village,Wichita,Chesterfield,Toms River,New York,New York,Staten Island,Matthews,North Canton,Oklahoma City,Por, Argentina,Australia,Canada,Finland,France,Germany,Italy,Netherlands,Norway,South Korea,Spain,Sweden,

Timeline & Enrollment

Phase 2

Oct 11, 2023

May 16, 2029

282 participants

Primary Outcome

Change from Baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score for Dose 1 vs Placebo Across Weeks 52, 64 and 76

Summary

The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with
 early Alzheimer's Disease (AD) (including mild cognitive impairment [MCI] and mild dementia
 due to AD) of 2 dose levels of GSK4527226 compared to placebo.

ICD-10 Classifications

Alzheimer disease
Alzheimer disease, unspecified
Other Alzheimer disease
Dementia in Alzheimer disease
Dementia in Alzheimer disease, unspecified

Data Source

ClinicalTrials.gov

NCT06079190

Non-Device Trial